No quarterly revenue total was found in Disc Medicine, Inc.'s SEC filings.
Disc Medicine, Inc. (IRON) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$40.2 million. As of Sep 30, 2026 it held $682.8 million in cash and investments and $61.1 million in total debt.
Revenue
—
Net income
$-59.53M
+4.5% vs year-ago quarter
Operating cash flow
$-40.20M
+15.9% vs year-ago quarter
Free cash flow
$-40.20M
+15.9% vs year-ago quarter
EPS
$-1.53
+13.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
45.54M
+20.6% vs year-ago quarter
Net cash
$621.73M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IRON (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Watertown, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1816736
- Former names
- Gemini Therapeutics, Inc. /DE (until Dec 28, 2022); FS Development Corp. (until Feb 8, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$64.2M | -$65.1M | -$69.5M | -$67.0M | -$67.7M |
| Net income | -$59.5M | -$59.5M | -$63.5M | -$60.5M | -$62.3M |
| Diluted EPS | -$1.53 | -$1.54 | -$1.65 | -$1.61 | -$1.77 |
| Operating cash flow | -$40.2M | -$44.2M | -$62.2M | -$43.3M | -$47.8M |
| Free cash flow | -$40.2M | -$44.2M | -$62.2M | -$43.3M | -$47.8M |
| Total assets | $699.5M | $735.1M | $750.2M | $806.9M | $630.5M |
| Total liabilities | $95.2M | $90.9M | $61.8M | $67.1M | $57.1M |
| Stockholders' equity | $604.2M | $644.2M | $688.4M | $739.8M | $573.4M |
| Cash and investments | $682.8M | $717.7M | $730.2M | $791.2M | $615.9M |
| Total debt | $61.1M | $60.9M | $31.1M | $30.7M | $31.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Material agreement, Results of operations, Other events
|
Oct 22, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 19, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 10, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
All 778 Disc Medicine, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.